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Introduction: Inﬂ ammation is a core feature of acute chronic obstructive pulmonary 
disease (COPD) exacerbations. It is important to focus on inﬂ ammation since it gives insight 
into the pathological changes causing an exacerbation, thereby possibly providing directions 
for future therapies which modify inﬂ ammation.
Objectives: To provide a cell-by-cell overview of the inﬂ ammatory processes during COPD 
exacerbations. To evaluate cell activation, and cytokine production, cellular interactions, 
damaging effects of inﬂ ammatory mediators to tissue, and the relation to symptoms at 
the onset of COPD exacerbations. To speculate on future therapeutic options to modify 
inﬂ ammation during COPD exacerbations.
Results: During COPD exacerbations, there is increased airway wall inﬂ ammation, with 
pathophysiological inﬂ ux of eosinophils, neutrophils, and lymphocytes. Although links have 
been suggested between the increase in eosinophils and lymphocytes and a viral etiology 
of the exacerbation, and between the increase in neutrophils and a bacterial aetiology, these 
increases in both inﬂ ammatory cell types are not limited to the respective aetiologies and the 
underlying mechanisms remain elusive. 
Conclusion: Further research is required to fully understand the inﬂ ammatory mechanisms 
in the onset and development of COPD exacerbations. This might make inﬂ ammatory 
pathway-speciﬁ c intervention possible, resulting in a more effective treatment of COPD 
exacerbations with fewer side effects. 
Keywords: COPD, exacerbation, inﬂ ammation, therapy
Introduction
Exacerbations are an important feature of chronic obstructive pulmonary disease 
(COPD) since they result in deterioration of a patient’s quality of life (Seemungal et al 
1998), contribute to decline in lung function (Donaldson et al 2002), and lead to over 
50% of all COPD-related costs (Rutten-van Molken et al 1999; McGuire et al 2001). 
A disease state with such important consequences is in need of a tight deﬁ nition, yet 
there is no consensus on such a deﬁ nition. Several deﬁ nitions have been proposed, 
focussing mostly on symptoms, sometimes in combination with infectious etiology 
(Madison and Irwin 1998; Davies et al 1999; Rodriguez-Roisin 2000). The most quoted 
deﬁ nition is the one proposed by Anthonisen ie, a disease state characterized by an 
increase in symptoms of dyspnea, sputum volume and sputum purulence (Anthonisen 
et al 1987). Although many physicians consider an increase in inﬂ ammation as a core 
feature of an acute COPD exacerbation and indeed several studies provide evidence 
that this is the case, (see later in this review), none of the deﬁ nitions in use for acute 
exacerbations capture the term inﬂ ammation. A ﬁ rst effort using inﬂ ammatory bio-
markers to objectively conﬁ rm COPD exacerbations has been published recently. This 
study showed that plasma C-reactive protein in combination with one major symptom 
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is useful to conﬁ rm an exacerbation of COPD (Hurst et al 
2006a). It is important to focus on inﬂ ammation, since it gives 
insight into the pathological changes causing an exacerbation, 
thereby possibly providing directions for future therapies 
which modify inﬂ ammation.
Bronchodilators and corticosteroids are the most com-
monly used drugs to treat exacerbations of COPD. Corti-
costeroids elicit a very broad array of anti-inﬂ ammatory 
actions. The use of systemic corticosteroids as treatment in 
COPD exacerbations is evidence-based (Wood-Baker et al 
2005). The beneﬁ cial clinical effects have been extensively 
investigated, but less is known of the underlying anti-inﬂ am-
matory effects of corticosteroids in exacerbations of COPD. 
In humans, only one placebo-controlled study (published in 
abstract form, see Bathoorn et al 2006) has investigated the 
anti-inﬂ ammatory mechanisms of steroids in COPD exacer-
bations, showing a suppressive effect of corticosteroids on 
sputum eosinophils.
It is difﬁ cult but certainly not impossible to study aspects 
of inﬂ ammation even during acute exacerbations of COPD. 
For instance, it has been shown that sputum can safely 
be induced also in patients with severe airﬂ ow limitation 
(Bhowmik et al 1998; Pizzichini et al 2002). Furthermore, 
techniques such as exhaled breath condensate can be applied 
but their repeatability is poor and it is uncertain which com-
partment (luminal, bronchial wall, alveolar, and parenchyma) 
the measured biomarkers reﬂ ect. More invasive assessment 
of inﬂ ammation in speciﬁ c lung compartments by bronchial 
biopsy, broncho-alveolar lavage, and theoretically even 
transbronchial biopsy is severely restricted during acute exac-
erbations for obvious safety and ethical reasons. Evaluating 
autopsies of patients who died during COPD exacerbations 
would be very informative, but, to the best of our knowl-
edge there are no reports of histopathology of lung tissue of 
patients deceased during COPD exacerbation.
The information on inﬂ ammation in COPD exacerba-
tions is fragmentary so far, because mainly cross-sectional 
information has been obtained during exacerbations without 
information during the prior stable state and only occasion-
ally information after the resolution of the exacerbation. Such 
information is necessary, since it will allow dissection of the 
predisposing factors, types of exacerbations, and patterns 
of resolution. The majority of information on inﬂ ammation 
during exacerbations in COPD is derived from studies using 
sputum inductions. Induced sputum is preferred to spontaneous 
sputum, since not all patients produce sputum spontaneously, 
and induced sputum contains higher percentage viable cells 
(Bhowmik et al 1998).
Many factors have to be taken into account when assess-
ing inﬂ ammation in acute exacerbations of COPD, given the 
mixed etiology of these COPD exacerbations. The major 
causes of exacerbations which have been identiﬁ ed are 
viral and bacterial infection, and air pollution (Sunyer et al 
1993; Fabbri and Hurd 2003). In approximately a third of 
all exacerbations a cause cannot be identiﬁ ed (White et al 
2003). Certainly the different known causes of exacerbation 
will result in various types of inﬂ ammation (Papi et al 2006). 
Furthermore, concomitant use of medication such as inhaled 
or oral corticosteroids have to be taken into account, since 
they affect the type of inﬂ ammation (Barnes et al 2006).
The aim of the current review is to provide a cell-by-cell 
overview of the inflammatory processes during COPD 
exacerbations. We will evaluate cell numbers, activation, 
and cytokine production, cellular interactions, damaging 
effects of inﬂ ammatory mediators to tissue, and the relation 
to symptoms at the onset of COPD exacerbations. We also 
speculate on future therapeutic options to modify inﬂ amma-
tion during COPD exacerbations.
Infl ammation
Neutrophils
Neutrophil numbers are slightly, but signiﬁ cantly increased 
in bronchial glands, submucosa, and in subepithelial tissue 
in bronchial biopsies in stable COPD, compared with healthy 
persons (smokers or nonsmokers), and the numbers of neu-
trophils positively related to severity of the airﬂ ow limitation 
(Saetta et al 1997; Di Stefano et al 1998; Rutgers et al 2000). 
The latter might result from bacterial colonisation, which may 
be present in sputum in the case of severe airﬂ ow limitation 
(Banerjee et al 2004; Sethi et al 2006).
In COPD exacerbations, neutrophils are increased in both 
the submucosa and subepithelial tissue compared with the 
stable disease (Qiu et al 2003; Fujimoto et al 2005; Mercer 
et al 2005; Tsoumakidou et al 2005b; Bathoorn et al 2006; 
Papi et al 2006). The presence of potential pathogenic micro-
organisms in sputum in exacerbations is associated with higher 
neutrophil numbers (Gompertz et al 2001), as in stable disease. 
Exacerbations are associated with increased sputum neutrophil 
numbers and the change in neutrophil numbers correlate with 
greater decrease in forced expiratory volume in one second 
(FEV
1
) during exacerbations (Papi et al 2006; Wilkinson et al 
2006) (Figure 1). At the time of the resolution of exacerbations, 
a decrease in neutrophil number is associated with eradica-
tion of bacteria from sputum (White et al 2003). A postulated 
underlying mechanism for this neutrophilia is the interaction 
of bacteria with Toll-like receptors on antigen presenting cells 
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and epithelial cells by bacteria, which induces the release of 
pro-inﬂ ammatory cytokines, as with viral infections (Wetzler 
2003; Ritter et al 2005). Although neutrophils show a relation 
with the presence of bacteria in both stable COPD and exacer-
bations, the increase in neutrophils is not limited to bacterial 
exacerbations: neutrophils have been shown to increase also 
during exacerbations associated with viral infections and in 
those without demonstrable pathogens (Papi et al 2006).
The most potent chemoattractants of neutrophils are 
leukotriene B4, interleukin-8 (IL-8), epithelial-derived neu-
trophil attractant-78, and tumor necrosis factor-α (TNF-α) 
(Saetta et al 1994; Bathoorn et al 2005; Fujimoto et al 2005; 
Mercer et al 2005; Papi et al 2006). COPD patients with frequent 
exacerbations have higher IL-8 levels in sputum in the stable 
phase compared to patients with infrequent exacerbations, 
illustrating the important role of neutrophil chemoattraction in 
the pathophysiology of COPD exacerbations (Tumkaya et al 
2007). The recruitment of neutrophils is facilitated by increased 
expression of adhesion molecules on the surface of circulating 
neutrophils, which are stress-inducible and up-regulated during 
COPD exacerbations (Albelda 1991; Selby et al 1991; Noguera 
et al 1998). Leukotrienes are also very potent chemoattractants 
of inﬂ ammatory cells during COPD exacerbations. Not only 
leukotriene B4, but also leukotriene E4 is increased during 
exacerbations and related to blood oxygen tension and airway 
obstruction in the course of exacerbations (Shindo et al 1997; 
Gompertz et al 2001; Biernacki et al 2003).
One of the main functions of neutrophils is their 
antibacterial role. To kill bacteria, neutrophils degranulate, 
releasing myeloperoxidase, a highly reactive acidic oxidant 
(Furtmuller et al 2000), which is increased during COPD 
exacerbations, both in sputum and serum (Aaron et al 2001).
Chronic obstructive pulmonary disease exacerbations 
caused by bacterial infections resulting in increased sputum 
neutrophils, often evoke a systemic inﬂ ammatory response: 
inﬂ ammatory markers such as circulating neutrophil num-
bers, C-reactive protein, ﬁ brinogen, and serum IL-6 are 
increased during exacerbations (Wedzicha et al 2000; Hurst 
et al 2006a, 2006b). Several mechanisms have been proposed 
for the origin of the increased systemic inﬂ ammation. These 
include:1) spill over of inﬂ ammatory mediators from the 
pulmonary compartment; 2) an inﬂ ammatory reaction to tis-
sue hypoxia; 3) a reaction induced by the pro-inﬂ ammatory 
bacterial product lipopolysaccharide (Wouters 2005).
Systemic inﬂ ammation could be important in the fol-
low-up of exacerbations, since COPD patients with frequent 
exacerbations have a smaller reduction of systemic inﬂ amma-
tory markers in the recovery of an exacerbation, and nonre-
covery of an exacerbation is related to persistently increased 
systemic inﬂ ammation (Perera et al 2007). Furthermore, 
systemic inﬂ ammation during COPD exacerbations may 
induce cardiovascular co-morbidity, by causing hemostasis 
and thrombosis. However, a relationship between increased 
inﬂ ammation caused by infections during exacerbations and 
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Figure 1 An increase in neutrophils concurs with a drop in FEV1 during a COPD exacerbation. Data of 64 patients. Copyright © 2006. Reproduced with permission from 
from Papi A, Bellettato CM, Braccioni F et al 2006. Infections and airway infl ammation in chronic obstructive pulmonary disease severe exacerbations.  Am J Respir Crit Care 
Med, 173:1114–21.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.
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the risk for cardiovascular heart disease has yet not been 
proven (Wedzicha et al 2000; Rothenbacher et al 2003; 
MacCallum 2005).
In conclusion, neutrophils are predominantly increased 
in more severe exacerbations caused by bacterial infections, 
however this increase is not limited to bacteria-associated 
exacerbations alone.
Eosinophils
Eosinophilic inflammation is generally not associated 
with COPD. In a stable phase, there is little evidence for a 
role of eosinophils except in a speciﬁ c COPD phenotype, 
which shows little emphysema and bronchial wall thicken-
ing on computed tomography scans and a good response 
to corticosteroids (Pizzichini et al 1998; Fujimoto et al 
1999; Brightling et al 2001, 2005; Kitaguchi et al 2006). 
This COPD phenotype has many features of asthma, and it 
would be of interest to compare in airway tissue histology 
from patients with this particular COPD phenotype and 
that of asthma patients. During COPD exacerbations it is 
recognised that an “asthma-like” inﬂ ammatory pattern in 
the airways may exist with increased numbers of eosinophils 
(Barnes 2000). At least 5 studies have found this in mild to 
moderate COPD exacerbations in airway wall biopsies, and 
by broncho-alveolar lavage and sputum induction, although 
some of these studies also included patients with chronic 
bronchitis without airway obstruction (17; 19; 27–29) 
(Figure 2). The increase in eosinophils during exacerbations 
shown in Figure 2 suggests that there is a subset of patients 
in which airway eosinophilia increases. The increase in 
eosinophils during COPD exacerbations is at least partially 
related to viral infections (Papi et al 2000; Rohde et al 2004). 
Pathogens are recognized by Toll-like receptors on epithelial 
cells, which induce the release of several pro-inﬂ ammatory 
cytokines (Hewson et al 2005; Ritter et al 2005). The eosino-
phil attracting chemokines “Regulated upon Activation, 
Normal T-cell Expressed, and Secreted” (RANTES), eotaxin, 
and interleukin-5 (IL-5) have been reported to be increased 
during COPD exacerbations (Zhu et al 2001; Bocchino et al 
2002; Rohde et al 2004; Fujimoto et al 2005).
Although, as documented above, the eosinophil has 
been consistently shown to be associated with COPD exac-
erbations, many clinicians do not intuitively consider this a 
relevant cell to target in the treatment of exacerbations. It is 
interesting, however, to realise that the eosinophil is the most 
steroid sensitive cell in the airways and that much of what is 
achieved with corticosteroids during exacerbations may be 
related to effects of steroids on eosinophils (Davies et al 1999; 
Niewoehner et al 1999). In stable COPD, it has been shown 
that higher number of eosinophils correlate with responsive-
ness to both oral and inhaled corticosteroids (Fujimoto et al 
1999; Brightling et al 2000, 2005). Additionally, it has been 
shown recently that both prednisolone and the combination of 
inhaled budesonide plus formoterol suppress sputum eosino-
philia during COPD exacerbations (Bathoorn et al 2006).
Whether this steroid-induced decrease in eosinophils has 
clinical beneﬁ t has not directly been proven. However, a 
decrease of soluble interleukin-5 receptor alpha in the resolu-
tion phase of a virus-induced exacerbation has been related 
to an increase in FEV
1
, suggesting that such a relationship 
may exist (Rohdeet al 2004).
Not only the eosinophils themselves, but also their 
products such as eosinophil cationic protein are increased in 
sputum and in serum during COPD exacerbations (Fiorini et al 
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Figure 2 Changes in sputum eosinophil numbers from stable phase of COPD to the onset of an exacerbation. Copyright © 2005. Reproduced with permission Fujimoto K, 
Yasuo M, Urushibata K et al 2005. Airway infl ammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J, 25:640–6.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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2000; Fujimoto et al 2005). Eosinophil cationic protein among 
other effects causes tissue damage and tissue remodelling in 
in vitro studies (Zagai et al 2004). This could explain at least 
part of the association between exacerbation frequency and 
excess decline in lung function (Donaldson et al 2002).
Lymphocytes
Stable disease
Lymphocytes are thought to play an important role in the develop-
ment and progression of COPD. Particularly CD8+ lymphocytes 
have been intensively investigated. CD8+ cells are increased 
in the airway submucosa and in peripheral blood in patients 
with stable COPD, and the number of CD8+ cells is positively 
related to the severity of airﬂ ow limitation (de Jong et al 1997; 
O’Shaughnessy et al 1997; Roland et al 2001). Most CD8+ cells 
are supposed to represent cytotoxic memory cells, which are 
produced after a ﬁ rst airway infection, and facilitate a faster and 
more effective response of the immune system when the next 
infection occurs. Indeed, in vivo studies show that more effec-
tive airway viral clearance is associated with higher CD8+ cell 
numbers. CD8+ cell numbers in the airways remain high for 
several months after viral infections, and stabilize after 6 months 
(Hou et al 1992; Liang et al 1994; Hogan et al 2001). The higher 
CD8+ numbers in stable COPD patients may be caused by the 
occurrence of an airway infection in the preceding few months, 
or alternatively there is a continuous low grade infection and the 
numbers of CD8+ cells reﬂ ect the need to protect the lung tissue 
(Matsuse et al 1992; Retamales et al 2001; Woodland and Scott 
2005). CD4+ cells, the helper T cells which produce pro-inﬂ am-
matory cytokines, have also been reported to be increased in 
the peripheral blood of patients with COPD, particularly the 
interferon gamma producing cells (Majori et al 1999).
Several recent studies have also shown that B-cells are 
increased in bronchiolar and bronchial walls in the stable 
phase of COPD (Hogg et al 2004; Gosman et al 2006; van der 
Strate et al 2006). B-cells play a role in the humeral immune 
response, producing antibodies to antigens. The pathological 
role of the increased B-cells in COPD is still uncertain. It 
has been speculated that viral airway infections may underlie 
the rise in B-cells (Gerhard et al 1997; Coro et al 2006), but 
an autoimmune response, perhaps in reaction to cigarette 
smoke components or extracellular matrix products has also 
been postulated (Majo et al 2001; Agusti et al 2003; van der 
Strate et al 2006).
Exacerbations
During exacerbations lymphocytes in both induced sputum 
and tissue biopsies increase even further (Saetta et al 1994; 
Fujimoto et al 2005; Mercer et al 2005; Bathoorn et al 2006) 
(Figure 3). This could partly be explained by the role of lympho-
cytes in the clearance of viruses. Despite consistent reports 
of the involvement of lymphocytes in COPD exacerbations, 
little data has been published on the lymphocyte subpopula-
tions which are involved. In a small study, a CD8 type 2 medi-
ated immune reaction occurred during COPD exacerbations 
(Tsoumakidou et al 2005a). To the best of our knowledge, 
no information on B-cells in COPD exacerbations has been 
published. We have no real insight on whether the changes 
in lymphocytes during exacerbations are a normal appropri-
ate, an insufﬁ cient, or even an inappropriate or excessive 
response. If the response is insufﬁ cient, higher levels of 
speciﬁ c lymphocytes may be more protective. Vaccination 
might be an intervention to increase the levels of speciﬁ c 
lymphocytes. To explore whether vaccinations could be an 
effective intervention to prevent COPD exacerbations, more 
insight on the role of the lymphocyte and their subpopula-
tions is needed. A large observational trial aiming to assess 
the role of T-cells in COPD exacerbations, which has started 
recruiting, will hopefully provide more information on this 
topic (ClinicalTrials.gov Identiﬁ er: NCT00281229).
In summary, airway infections are a common cause of 
COPD exacerbations, and as lymphocytes are the regulatory 
cells of immune response to infections, they could very well 
be key-players in the increased inﬂ ammation in both stable 
COPD and in the onset of COPD exacerbations, but the exact 
mechanisms by which the inﬂ ux of cells is generated, their 
activation state, and their resulting effects still need to be 
elucidated.
Macrophages
Smokers with stable COPD have increased numbers of 
macrophages in airway tissue compared with chronic bron-
chitic patients without airﬂ ow limitation, or healthy controls 
(O’Shaughnessy et al 1997). The increase in macrophages is 
induced by smoking, since cessation of smoking in asymp-
tomatic persons results in a decrease in sputum macrophages, 
and current smoking is positively related to macrophage 
numbers in airway submucosa and tissue (Willemse et al 
2005a, 2005b).
During exacerbations of COPD, large observational stud-
ies have not shown a signiﬁ cant increase in sputum or airway 
tissue macrophages, neither as a percentage of total cells 
nor as an increase in absolute cell counts (Saetta et al 1994; 
Bhowmik et al 2000; Fujimoto et al 2005; Papi et al 2006). 
One study has even shown a signiﬁ cant decrease in sputum 
macrophages as percentage (Tsoumakidou et al 2005a). 
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However, it is perhaps too early to conclude that macrophages 
are not involved during exacerbations. Since macrophages 
are responsive to cigarette smoke, a reduction in the number 
of cigarettes smoked during exacerbations could perhaps 
mask an increase in macrophages compared to the stable 
phase of disease. Future studies analyzing the inﬂ ammatory 
changes for nonsmokers separately could perhaps give a 
more deﬁ nitive answer whether macrophages are increased 
during COPD exacerbation.
Air pollution
Epidemiological studies have shown that air pollution, 
particularly with ﬁ ne particulate matters, can cause of 
COPD exacerbations (Sunyer et al 1993; Seaton et al 
1995). Air pollution is associated with increased inﬂ am-
mation in the airways of elderly people, as they have 
higher exhaled nitric oxide levels when airway pollution 
increases (Adamkiewicz et al 2004). There is a lack of 
data on cellular airway inﬂ ammation caused by airway 
pollution induced COPD exacerbations, probably since 
it is difﬁ cult to identify these exacerbations caused by air 
pollution singularly, and since air pollution also interacts 
with viruses, resulting in a mixed origin of the exacerbation 
(Gilmour et al 2001).
Oxidative stress
Oxidative stress is an imbalance between the amount of 
oxidants and the capacity of antioxidants to scavenge 
these radicals. This imbalance originates from either an 
increased load of oxidants (reactive oxygen and nitrogen 
species and free radicals) and/or by a decreased antioxidant 
capacity. The increase in oxidants may result from release 
from inﬂ ammatory cells, or caused by increased inhalation 
of oxidants in cigarette smoke or polluted air (Church and 
Pryor 1985; Morrison et al 1999; Becker et al 2002). Oxida-
tive stress induces Nuclear Factor-κB, a transcription factor 
involved in upregulating genes of many pro-inﬂ ammatory 
cytokines, resulting in increased inﬂ ammation (Rahman 
and MacNee 1998). Thus, inﬂ ammation induces oxida-
tive stress and oxidative stress in turn causes increased 
inﬂ ammation.
Furthermore, the oxidative stress can be caused by a 
decreased antioxidant capacity. Theoretically, a decreased 
antioxidant capacity might result from poor nutritional 
status, however reports on the effect of food intake on the 
antioxidant capacity is conﬂ icting (Cao et al 1998; Record 
et al 2001). However, an increased oxidant burden may 
lead to depletion of antioxidants in epithelial lining ﬂ uid in 
exacerbations of COPD (98). Another possibility could be 
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a dysfunction of antioxidant producing enzymes (Yamada 
et al 2000; Hersh et al 2005).
During exacerbations, the antioxidant capacity is 
decreased, both in blood and in the airway submucosa 
(Rahman et al 1997; Drost et al 2005). This decrease in 
antioxidant capacity is probably caused by an increased 
requirement for the scavenging of oxidants, since hydroxy-
genperoxidase and 8-isoprostane, both products of reactions 
with oxygen radicals, are increased during COPD exacerba-
tions in exhaled breath condensate (Biernacki et al 2003; 
Gerritsen et al 2005; Oudijk et al 2006).
Thus, oxidative stress is involved in COPD exacerba-
tions, since there is an increased load of oxidants and 
the antioxidant capacity is decreased. It cannot be deter-
mined whether oxidative stress is a pathogenic cause of 
exacerbations, or a consequence of increased inhalation of 
oxidants, or infection with an increased inﬂ ammation.
Anti-infl ammatory therapies
Modiﬁ cation of inﬂ ammation during COPD exacerbations is 
not without potential risks, since inﬂ ammatory cells play a role 
in defence against pathogens. Ideally any modiﬁ cation should 
improve symptoms and inﬂ ammatory damage, without increas-
ing the risk of consequent infections. In vivo models of COPD 
exacerbations would be useful to test new anti-inﬂ ammatory 
drugs. Unfortunately, successful in vivo models for COPD 
exacerbations have not yet been reported as far as we know.
The only proven successful inﬂ ammation modifying 
therapy for COPD exacerbations thus far is treatment with 
corticosteroids. Treatment of COPD exacerbations with 
systemic corticosteroids improves lung function and oxy-
genation, reduces treatment failures, and shortens the length 
of hospital stay (Thompson et al 1996; Davies et al 1999; 
Niewoehner et al 1999; Maltais et al 2002). These beneﬁ cial 
effects are evidence based, however the magnitude of effect 
is modest. Lung function improves in the ﬁ rst 72 hours of 
treatment, but the improvement is not signiﬁ cantly different 
compared to placebo treatment after 2 weeks suggesting a 
spontaneous recovery in many patients. The reduction in 
length of hospitalisation with systemic steroids is 1–2 days 
(Davies et al 1999; Niewoehner et al 1999; Maltais et al 
2002). However, these gains with steroid treatment come at 
a price. Treatment with systemic corticosteroids results in 
adverse systemic effects, such as hyperglycaemia, insomnia, 
and weight gain (Davies et al 1999; Maltais et al 2002; Aaron 
et al 2003). It has been calculated that one extra adverse effect 
occurs for every 6 patients treated with systemic corticoste-
roids (Wood-Baker et al 2005).
To avoid systemic adverse effect of oral steroids, 
treatment with inhaled steroids at an increased dose com-
pared to the maintenance dose might be an option. Indeed, 
in one study treatment of COPD exacerbations with inhaled 
steroids improved lung function compared to placebo treat-
ment, and caused less systemic effects than systemic steroid 
treatment (Maltais et al 2002). Since maximal bronchodila-
tion and steroids are the current standard treatment of COPD 
exacerbations, combined long-acting bronchodilators, and 
inhaled steroids is a logical next intervention. A single 
study has investigated treatment of COPD exacerbations 
with combined budesonide and formoterol, which resulted 
in a decrease in sputum eosinophils, and an improvement of 
symptoms and health status (Bathoorn et al 2006). A larger 
study powered to document improvement in airﬂ ow limita-
tion is under way and investigates whether this combined 
therapy is as effective as systemic steroids in the treatment 
of COPD exacerbations (ClinicalTrials.gov Identifier: 
NCT00259779).
The data on inﬂ ammation that observational studies of 
COPD exacerbations have provided, can potentially lead 
to development of novel inﬂ ammation modifying drugs. 
Some of these drugs have already been tested in the stable 
phase of COPD, and could be beneﬁ cial in the treatment of 
exacerbations.
Modiﬁ cation of inﬂ ammation by leukotriene antagonists 
has been tested in the treatment of stable COPD (Barnes 
1989; Celik et al 2005). Both treatment of stable COPD 
patients with montelukast, a leukotriene receptor antagonist, 
and with BAYx1005 a leukotriene synthesis inhibitor resulted 
in a reduction in neutrophil numbers in sputum. Leukotriene 
B4 has been shown to be involved in the chemoattraction 
of neutrophils during exacerbations (Biernacki et al 2003). 
Therefore, treatment to reduce leukotriene levels might also 
be beneﬁ cial in COPD exacerbations.
Phosphodiesterase (PDE)-4 inhibition is an anti-
inﬂ ammatory mechanism that inhibits the break down of cyclic 
adenosine monophosphate in inﬂ ammatory cells (Barnette 
1999). This results in higher intracellular cyclic adenosine 
monophosphate, which inactivates pro-inﬂ ammatory tran-
scription factors by protein kinase A. Trials in patients with 
stable COPD showed improvements in lung function, quality 
of life, and exacerbation rates with this treatment (Rabe et al 
2005; Rennard et al 2006). A reduction of bronchial wall 
CD8+ cells and macrophages has been demonstrated in stable 
disease, but the effect was rather small (Gamble et al 2003; 
Kerstjens and Timens 2003). PDE-4 inhibitors have not been 
tested in the treatment of COPD exacerbations.
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Tumor necrosis factor-α is a general pro-inﬂ ammatory 
cytokine, and its levels are increased in sputum at the onset 
of COPD exacerbations (Aaron et al 2001). Inhibition of 
TNF-α could lead to a reduction in inﬂ ammation during 
COPD exacerbations. Systemic anti-TNF-α administration 
has been tested in 22 patients with mild-to moderate COPD, 
yet in a stable phase of disease (van der Vaart et al 2005). 
This study showed no positive effects. Perhaps more severe 
COPD, or more speciﬁ cally COPD exacerbations, would be 
an appropriate indication for anti-TNF-α treatment.
Inhibition of cytokines involved in the recruitment of 
eosinophils, such as IL-5, RANTES, and eotaxin could also be 
a strategy to modify inﬂ ammation during COPD exacerbations. 
This has not been studied in COPD so far. In vitro studies and 
studies in patients with asthma show beneﬁ cial effects of such 
speciﬁ c antieosinophil therapies, and perhaps these therapies 
should be tested as a treatment of COPD exacerbations (Elsner 
et al 1997; Heath et al 1997; Teixeira et al 1997; Proudfoot et al 
1999; Leckie et al 2000; Chvatchko et al 2003; Flood-Page 
et al 2003; Kumar et al 2004; Tanaka et al 2004).
Another pathway to reduce inﬂ ammation is inhibition 
of the mitogen-activated protein (MAP)-kinase pathway. 
MAP-kinase pathways are involved in the signal transduction 
from an external inﬂ ammatory stimulus to an inﬂ ammatory 
response, by activating intracellular transcription factors 
for pro-inﬂ ammatory cytokine gene expression (Lee and 
Goodbourn 2001). In vivo studies investigating MAP-kinase 
inhibitors show reducing effects on neutrophil inﬂ ammation 
in a lipopolysaccharide inhalation model, and on eosinophilic 
inﬂ ammation in an allergy model (Underwood et al 2000; 
Chapman et al 2001). The ﬁ rst generation MAP-kinase 
inhibitors had signiﬁ cant side effects in humans. A second 
generation is in development with fewer side effects (Adams 
et al 1998) and might be introduced in the treatment of airway 
inﬂ ammatory diseases in the near future, including COPD 
exacerbations.
Macrolides are well known for their antimicrobial activ-
ity. Besides their antimicrobial activity, macrolides have anti-
inﬂ ammatory effects. They reduce pro-inﬂ ammatory cytokine 
production, and neutrophilic and eosinophilic inﬂ ammation 
(Gotfried 2004). Part of these anti-inﬂ ammatory effects 
involve the extracellular regulated protein kinase pathway, 
a MAP-kinase pathway (Shinkai et al 2006). Macrolide 
treatment in stable COPD patients induced a reduction in 
neutrophilic inﬂ ammation without improvement in health 
status or exacerbation rate (Banerjee et al 2005; Parnham et al 
2005). We did not ﬁ nd any reports on the effects of COPD 
exacerbations with macrolides compared to other antibiotics 
in relation to their anti-inﬂ ammatory properties.
Inhibition of MAP-kinase can also be established by 
inhalation of low dose carbon monoxide (CO) (Otterbein 
et al 2000). CO inhalation is usually associated with toxic 
Table 1 Studies reporting increased airway neutrophils during exacerbations compared with stable phase
Study Number of patients FEV1 % of predicted  Number of sputum % sputum neutrophils Method
 in stable phase/ in stable phase/ neutrophils in stable in stable phase/
 exacerbation exacerbation phase/exacerbation exacerbation
Papi et al 2006 64/64 49.5/39.4 9.5/26.7 × 106/grama nr Sputum induction
Tsoumakidou 2005 12/12 40/nr nr 83.5/98.0a Sputum induction
Bathoorn et al 2006 39/39 61/51 3.2/7.1 × 106/mLa 72.5/72.0 Sputum induction
Mercer et al 2005 19/12 nr/37.6 1.48/2.19 × 106/grama 80.0/87.5 Sputum induction
Fujimoto et al 2005 30/30 52.9/40.6 4.4/24.4 × 106/grama 83.4/81.7 Sputum induction
Balbi et al 1997 8/5 71/64 10/83 × 103/mLa nr/nr BAL
Notes: ap   0.05; nr, data not reported.
Table 2 Studies reporting increased airway eosinophils during exacerbations compared with stable phase
Study Number of patients FEV1 % of predicted Number of sputum % sputum eosinophils Method
 in stable phase/ in stable phase/ eosinophils in stable of in stable phase/
 exacerbation exacerbation phase/exacerbation exacerbation
Fujimoto et al 2005 30/30 52.9/40.6 0.1/1.3 × 106/grama 1.7/6.7a Sputum induction
Bathoorn et al 2006 39/39 61/51 0.1/0.4 × 106/mLa 2.7/2.8 Sputum induction
Mercer et al 2005 19/12 nr/37.6 0.01/0.07 × 106/grama 0.75/1.0 Sputum induction
Balbi et al 1997 8/5 71/64 1.9/6.7 × 103/mLa nr/nra BAL
Papi et al 2006 15/15 subgroup  nr/nr 0.9/3.5 × 106/grama nr/nr Sputum induction
 viral exacerbations
Notes: ap  0.05; nr, data not reported.
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effects which occur during exposure to high doses or to 
long-term low levels. In contrast, exposure to low dose CO 
can be cytoprotective (Otterbein and Choi 2000), and both 
in vitro and in vivo studies have shown its anti-inﬂ ammatory 
effects on the airways (Chapman et al 2001; Ameredes et al 
2003; Ning et al 2005). Inhalation of low dose CO in an 
ovalbumin-induced allergic in vivo model attenuates the 
eosinophilic inﬂ ammation by reducing IL-5 levels, and reduces 
bronchial hyperresponsiveness to methacholine (Figure 4). 
Therefore, CO has been postulated to have a potential 
Table 3 Studies reporting increased airway lymphocytes during exacerbations compared with stable phase
Study Number of patients FEV1 % of predicted  Number of sputum % sputum lymphocytes Method
 in stable phase/ in stable phase/ lymphocytes in stable in stable phase/
 exacerbation exacerbation phase/exacerbation exacerbation
   
Fujimoto et al 2005 30/30 52.9/40.6 0.2/0.7 × 106/grama 4.0/4.9 Sputum induction
Bathoorn et al 2006 39/39 61/51 0/0.1 × 106/mLa 0.3/0.7a Sputum induction
Mercer et al 2005 19/12 nr/37.6 0.03/0.31 × 106/grama 2.5/4.5 Sputum induction
Papi et al 2006 64/64 49.5/39.4 0.04/0.11 × 106/gramb nr Sputum induction
Notes: ap  0.05; bp = 0.06; nr, data not reported.
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Figure 4 In an aero-allergen induced allergic infl ammation mice model, inhaled carbon monoxide (CO) reduced infl ammatory cell counts (×104/mL) in broncho-alveolar lavage 
fl uid. Treated animals (CO) received 250 parts per million inhaled carbon monoxide 2 hours before the aero-allergen challenge (OVA) and continuously thereafter. Control 
animals were kept in room air (RA) for the duration of the experiment. Copyright © 2001. Reproduced with permission from Chapman JT, Otterbein LE, Elias JA et al 2001. 
Carbon monoxide attenuates aeroallergen-induced infl ammation in mice. Am J Physiol Lung Cell Mol Physiol, 281:L209–L216.
Notes: *Signifi cantly increased (p  0.05) from sham-challenged animals; †Signifi cantly different (p  0.05) from mice kept in room air; ††Signifi cantly different (p  0.0007) 
from mice kept in room air.
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therapeutic role in pulmonary medicine (Slebos et al 2003). 
The effects of inhaled CO have been tested in healthy 
volunteers, who were infused with lipopolysaccharide, but 
CO did not inﬂ uence plasma TNF-α, IL-6, and IL-8 levels, 
which were increased by lipopolysaccharide (Mayr et al 
2005). Since the predominant effect of CO seems to be 
a reduction of eosinophils, asthma and COPD exacerba-
tions could be more appropriate indications. The results of 
anti-inﬂ ammatory effects of inhaled CO on inﬂ ammatory 
airway diseases will appear in the near future (Bathoorn 
et al 2007).
Conclusions
During COPD exacerbations, there is increased airway wall 
inﬂ ammation, with pathophysiological inﬂ ux of eosino-
phils, neutrophils, and lymphocytes. There are no reports 
of increased macrophages during COPD exacerbations. 
Although links have been suggested between the increase 
in eosinophils and lymphocytes and a viral etiology of the 
exacerbation, and between the increase in neutrophils and 
a bacterial etiology, these increases in both inﬂ ammatory 
cell types are not limited to the respective etiologies and 
the underlying mechanisms remain elusive. Reports on 
increases in lymphocytes during COPD exacerbations are 
consistent, and they might play a key role in the protection 
against recurrent infections, which evoke an inﬂ ammatory 
response. There is little data on the subtypes of lympho-
cytes involved in the onset of COPD exacerbations, which 
would be essential to dissect the normal from the patho-
physiological immune response, which may be increased 
either excessively or insufﬁ ciently. Studies that document 
the onset of inﬂ ammatory changes in COPD exacerbations 
should prove useful to develop inﬂ ammation-modifying 
interventions.
The only successful inﬂ ammation-modifying drugs dur-
ing exacerbations so far are corticosteroids, but their beneﬁ -
cial effects are modest and steroids do have important side 
effects. New data suggest that the use of inhaled steroids (in 
combination with long-acting bronchodilators) may be an 
alternative to systemic steroids in the treatment of exacerba-
tions with less potential for systemic side effects. Whether 
this is as effective as systemic steroids needs to be assessed 
in future studies.
Several more speciﬁ c cytokine or pathway inhibiting 
drugs are in development for stable COPD. A further step 
might be to test these drugs also in COPD exacerbations. 
However, it is also possible that new drugs that speciﬁ cally 
target inﬂ ammatory changes pertinent to COPD exacerbations 
can be developed. In conclusion, further research is required 
to fully understand the inﬂ ammatory mechanisms in the 
onset and development of COPD exacerbations. This might 
make inﬂ ammatory pathway-speciﬁ c intervention possible, 
resulting in a more effective treatment of COPD exacerba-
tions with fewer side effects.
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